Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying

Chemical and Pharmaceutical Bulletin

Volumn 56, Issue 12, 2008, Pages 1645-1650

  Zhang, Xinxin ^a,b   Pan, Weisan ^a   Gan, Li ^b   Zhu, Chunliu ^b   Gan, Yong ^b   Nie, Shufang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

10 hydroxycamptothecin; Cellular uptake; Nanostructured lipid carrier; Polyethylene glycol; Spray drying

Indexed keywords

10 HYDROXYCAMPTOTHECIN; MACROGOL; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; DRUG STABILITY; DRUG UPTAKE; MACROPHAGE; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; SCANNING ELECTRON MICROSCOPE; SPRAY DRYING; X RAY POWDER DIFFRACTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALORIMETRY, DIFFERENTIAL SCANNING; CAMPTOTHECIN; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; DESICCATION; DOGS; DRUG CARRIERS; DRUG COMPOUNDING; LIPIDS; MACROPHAGES; NANOPARTICLES; PARTICLE SIZE; PHAGOCYTOSIS; POLYETHYLENE GLYCOLS; POWDERS; X-RAY DIFFRACTION;

EID: 57349084073     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.56.1645     Document Type: Article

References (21)

1. Jaxel C., Kohn K. W., Wani M. C., Wall M. E., Pommier Y., Cancer Res., 49, 1465-1469 (1989).
2. O'Leary J., Muggia F. M., Eur. J. Cancer, 34, 1500-1508 (1998).
3. Igor C., Jean M. M., Ganesh D. S., Jean F. R., Biochim. Biophys. Acta, 1379, 353-366 (1998).
4. Inaba M., Science, Sports and Culture of Japan, 1994, 57-61 (1994).
5. Müller R. H., Radtke M., Wissing S. A., Adv. Drug Deliv. Rev., 54 Suppl. 1, S131-S155 (2002).
6. Moghimi S. M., Hunter A. C., Murray J. C., Pharmacol. Rev., 53, 283-318 (2001).
7. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K., J. Controlled Release, 65, 271-284 (2000).
8. Saez M., Guzmán M., Molpereceres J., Aberturas M. R., Eur. J. Pharm. Biopharm., 50, 379-387 (2000).
9. Ammoury N., Fessi H., Devissaguet J. P., Dubrasquet M., STP Pharma Sci., 5, 537-540 (1989).
10. Magenheim B., Benita S., STP Pharma Sci., 1, 221-241 (1991).
11. Guterres S. S., Fessi H., Barratt G., Devissaguet J.-P., Puisieux F., Int. J. Pharm., 113, 57-63 (1995).
12. Cavalli R., Caputo O., Carlotti M. E., Trotta M., Scarnecchia C., Gasco M. R., Int. J. Pharm., 148, 47-54 (1997).
13. Chasteigner S., Fessi H., Cave G., Devissaguet J. P., Puisieux F., STP Pharma Sci., 5, 242-246 (1995).
14. Broadhead J., Edmond Rouan S. K., Rhodes C. T., Drug Dev. Ind. Pharm., 18, 1169-1206 (1992).
15. Zhang X. X., Gan Y., Gan L., Nie S. F., Pan W. S., J. Pharm. Pharmacol., 60, 1077-1087 (2008).
16. Kecht-Wyrsch P., "Ph.D. thesis, Eidgenössische Technische Hochschule Zürich," Zürich, 1987.
17. Peracchia M. T., Vauthier C., Passirani C., Couvreur P., Labrre D., Life Sci., 61, 749-761 (1997).
18. Desai M. P., Labhasetwar V., Walter E., Levy R. J., Amidon G. L., Pharm. Res., 14, 1568-1573 (1997).
19. Evangelos C. G., Maria H., Evangelia P., Konstantinos A., Eur. J. Pharm. Biopharm., 67, 1-8 (2007).
20. Zauner W., Farrow N. A., Hainess A. M. R., J. Controlled Release, 71, 39-51 (2001).
21. Jung T., Kamm W., Breitenbach A., Kaiserling E., Xiao J. X., Kissel T., Eur. J. Pharm. Biopharm., 50, 147-160 (2000).